Emerging research suggest Retatru tide , a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , could represent a promising advancement for weight management . Preliminary clinical trials have demonstrated impressive decreases in abdominal mass , conceivably outperforming existing obesity medications . However , f